$130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P., Cormorant Asset Management, Vivo Capital, Logos Capital, and Woodline Partners LP
Senior secured credit facility for up to $50 million provided by Silicon Valley Bank
Financing provides sufficient capital to fund Olema beyond OPERA-01 clinical trial top-line data and into 2027
https://www.biospace.com/article/olema-oncology-announces-combined-financing-for-up-to-180-million/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.